Pharmacogenetics of Colon Cancer and Potential Implications for 5- Fluorouracil-Based Chemotherapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-6204|4|1|57-67

ISSN： 1570-1603

Source： Current Pharmacogenomics, Vol.4, Iss.1, 2006-03, pp. : 57-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle

By LaBonte Melissa J   Lenz Heinz-Josef  

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1671-1674

Future Medicine

Access to resources Recommend Favorite

Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy

By Zhang Xue   Diasio Robert B  

Pharmacogenomics, Vol. 8, Iss. 3, 2007-03 ,pp. : 257-265

Future Medicine

Access to resources Recommend Favorite

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics

By Mattison Lori K   Soong Richie   Diasio Robert B  

Pharmacogenomics, Vol. 3, Iss. 4, 2002-07 ,pp. : 485-492

Future Medicine

Access to resources Recommend Favorite

Biweekly fluorouracil-based regimen in gastric cancer

By  

Inpharma, Vol. 1, Iss. 1426, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer

By Etienne-Grimaldi Marie-Christine   Francoual Mireille   Formento Jean-Louis   Milano Géérard  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1561-1566

Future Medicine

Access to resources Recommend Favorite